I'm still your baby: Canada's continuing support of U.S. linkage regulations for pharmaceuticals.

This document cites

• Federal Cases - 733 F.2d 858 (Fed. Cir. 1984), 84-560, Roche Products, Inc. v. Bolar Pharmaceutical Co., Inc.
• Federal Cases - 920 F.2d 984 (D.C. Cir. 1990), 89-5183, Abbott Laboratories v. Young
• Federal Cases - 268 F.3d 1323 (Fed. Cir. 2001), 01-1257, Mylan Pharmaceuticals, Inc. v. Thompson
• Federal Cases - 460 U.S. 824 (1983), 81-1273, Bowsher v. Merck & Co., Inc.
• Federal Cases - 550 U.S. 398 (2007), 04-1350, KSR International Co. v. Teleflex Inc.



See all quotations

• Federal Cases - 383 U.S. 1 (1966), 11, Graham v. John Deere Co. of Kansas City
• Bristol-Myers Squibb Co. et al. v. Canada (Attorney General) et al., (2005) 334 N.R. 55 (SCC)
• Merck Frosst Canada Inc. et al. v. Canada (Minister of National Health and Welfare) et al., (1998) 227 N.R. 299 (SCC)
• AstraZeneca Canada Inc. v. Canada (Minister of Health), [2006] 2 SCR 560
• Free World Trust v. Électro Santé Inc., [2000] 2 SCR 1024
• Whirlpool Corp. v. Camco Inc., 2000 SCC 67
• Apotex Inc. v. Canada (Attorney General), [1994] 3 SCR 1100
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)Text with EEA relevance
• General Agreement on Tariffs and Trade